Immune control of mammalian gamma-herpesviruses: Lessons from murid herpesvirus-4

Journal of General Virology

Volumn 90, Issue 10, 2009, Pages 2317-2330

  Stevenson, P G ^a   Simas, J P ^b   Efstathiou, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERPES VACCINE; LATENCY ASSOCIATED NUCLEAR ANTIGEN;

ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLYSIS; EPISOME; GENE EXPRESSION; HERPES VIRUS; HERPES VIRUS INFECTION; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MURID HERPES VIRUS 4; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; VIRION; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS VIRULENCE; ANIMAL; IMMUNOLOGY; MOUSE; PHYSIOLOGY; RHADINOVIRUS; T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ANIMALIA; HERPESVIRIDAE; HUMAN HERPESVIRUS 4; MAMMALIA; MURID HERPESVIRUS 4;

ANIMALS; HERPESVIRIDAE INFECTIONS; MICE; RHADINOVIRUS; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS;

EID: 70350503061     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.013300-0     Document Type: Review

References (147)

1. Adhikary, D., Behrends, U., Moosmann, A., Witter, K., Bornkamm, G. W. & Mautner, J. (2006). Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203, 995-1006.
2. Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. (1999). Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190, 567-576.
3. Baigent, S. J., Smith, L. P., Nair, V. K. & Currie, R. J. (2006). Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection. Vet Immunol Immunopathol 112, 78-86.
4. Battegay, M., Moskophidis, D., Rahemtulla, A., Hengartner, H., Mak, T. W. & Zinkernagel, R. M. (1994). Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 68, 4700-4704.
5. + T cells but confers minimal survival advantage on CD4-deficient mice. Proc Natl Acad Sci U S A 97, 2725-2730.
6. b-/- mice. J Gen Virol 84, 337-341.
7. Bennett, N. J., May, J. S. & Stevenson, P. G. (2005). Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol 3, e120.
8. Biggs, P. M. (1997). Marek's disease herpesvirus: oncogenesis and prevention. Philos Trans R Soc Lond B Biol Sci 352, 1951-1962.
9. + T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 165, 7078-7087.
10. Blaskovic, D., Stancekova, M., Svobodova, J. & Mistrikova, J. (1980). Isolation of five strains of herpesviruses from two species of free living small rodents. Acta Virol 24, 468.
11. Boname, J. M. & Stevenson, P. G. (2001). MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 15, 627-636.
12. Boname, J. M., de Lima, B. D., Lehner, P. J. & Stevenson, P. G. (2004a). Viral degradation of the MHC class I peptide loading complex. Immunity 20, 305-317.
13. Boname, J. M., Coleman, H. M., May, J. S. & Stevenson, P. G. (2004b). Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant. J Gen Virol 85, 131-135.
14. Bouma, A. (2005). Determination of the effectiveness of Pseudorabies marker vaccines in experiments and field trials. Biologicals 33, 241-245.
15. Bowden, R. J., Simas, J. P., Davis, A. J. & Efstathiou, S. (1997). Murine gammaherpesvirus 68 encodes tRNA-like sequences which are expressed during latency. J Gen Virol 78, 1675-1687.
16. Braaten, D. C., McClellan, J. S., Messaoudi, I., Tibbetts, S. A., McClellan, K. B., Nikolich-Zugich, J. & Virgin, H. W. (2006). Effective control of chronic gamma-herpesvirus infection by unconventional MHC Class Ia-independent CD8 T cells. PLoS Pathog 2, e37.
17. Bridgeman, A., Stevenson, P. G., Simas, J. P. & Efstathiou, S. (2001). A secreted chemokine binding protein encoded by murine gammaherpesvirus- 68 is necessary for the establishment of a normal latent load. J Exp Med 194, 301-312.
18. Burkhardt, A. L., Bolen, J. B., Kieff, E. & Longnecker, R. (1992). An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 66, 5161-5167.
19. + T cells in acute infectious mononucleosis. Nat Med 2, 906-911.
20. + T cells. J Exp Med 184, 863-871.
21. Carneiro-Sampaio, M. & Coutinho, A. (2007). Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun 75, 1545-1555.
22. Cerundolo, V. & de la Salle, H. (2006). Description of HLA class Iand CD8-deficient patients: insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin Immunol 18, 330-336.
23. Chastel, C., Beaucournu, J. P., Chastel, O., Legrand, M. C. & Le Goff, F. (1994). A herpesvirus from an European shrew (Crocidura russula). Acta Virol 38, 309.
24. + T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-γ. Proc Natl Acad Sci U S A 96, 5135-5140.
25. Coleman, H. M., Brierley, I. & Stevenson, P. G. (2003a). An internal ribosome entry site directs translation of the murine gammaherpesvirus 68 MK3 open reading frame. J Virol 77, 13093-13105.
26. Coleman, H. M., de Lima, B., Morton, V. & Stevenson, P. G. (2003b). Murine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latency. J Virol 77, 2410-2417.
27. Davenport, M. G. & Pagano, J. S. (1999). Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J Virol 73, 3154-3161.
28. de Lima, B. D., May, J. S. & Stevenson, P. G. (2004). Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 78, 5103-5112.
29. de Lima, B. D., May, J. S., Marques, S., Simas, J. P. & Stevenson, P. G. (2005). Murine gammaherpesvirus 68 bcl-2 homologue contributes to latency establishment in vivo. J Gen Virol 86, 31-40.
30. Dutia, B. M., Clarke, C. J., Allen, D. J. & Nash, A. A. (1997). Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: a role for CD8 T cells. J Virol 71, 4278-4283.
31. Ehtisham, S., Sunil-Chandra, N. P. & Nash, A. A. (1993). Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol 67, 5247-5252.
32. + T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82, 1448-1457.
33. Epstein, M. A., Achong, B. G. & Barr, Y. M. (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702-703.
34. Faulkner, G. C., Krajewski, A. S. & Crawford, D. H. (2000). The ins and outs of EBV infection. Trends Microbiol 8, 185-189.
35. Fowler, P. & Efstathiou, S. (2004). Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73. J Gen Virol 85, 609-613.
36. Fowler, P., Marques, S., Simas, J. P. & Efstathiou, S. (2003). ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J Gen Virol 84, 3405-3416.
37. Früh, K., Bartee, E., Gouveia, K. & Mansouri, M. (2002). Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res 88, 55-69.
38. + T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 114, 542-550.
39. Gangappa, S., Kapadia, S. B., Speck, S. H. & Virgin, H. W. (2002). Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice. J Virol 76, 11460-11468.
40. Gill, M. B., Gillet, L., Colaco, S., May, J. S., de Lima, B. D. & Stevenson, P. G. (2006). Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies. J Gen Virol 87, 1465-1475.
41. Gill, M. B., Wright, D. E., Smith, C. M., May, J. S. & Stevenson, P. G. (2009). Murid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization. J Gen Virol 90, 1461-1470.
42. Gillet, L. & Stevenson, P. G. (2007a). Evidence for a multiprotein gamma-2 herpesvirus entry complex. J Virol 81, 13082-13091.
43. Gillet, L. & Stevenson, P. G. (2007b). Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO J 26, 5131-5142.
44. Gillet, L., Gill, M. B., Colaco, S., Smith, C. M. & Stevenson, P. G. (2006). Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice. J Gen Virol 87, 3515-3527.
45. Gillet, L., May, J. S. & Stevenson, P. G. (2007a). Post-exposure vaccination improves gammaherpesvirus neutralization. PLoS One 2, e899.
46. Gillet, L., May, J. S., Colaco, S. & Stevenson, P. G. (2007b). The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization. PLoS One 2, e705.
47. Gillet, L., Colaco, S. & Stevenson, P. G. (2008a). Glycoprotein B switches conformation during murid herpesvirus 4 entry. J Gen Virol 89, 1352-1363.
48. Gillet, L., Colaco, S. & Stevenson, P. G. (2008b). The murid herpesvirus-4 gL regulates an entry-associated conformation change in gH. PLoS One 3, e2811.
49. Gillet, L., May, J. S. & Stevenson, P. G. (2009a). In vivo importance of heparan sulfate-binding glycoproteins for murid herpesvirus-4 infection. J Gen Virol 90, 602-613.
50. Gillet, L., Alenquer, M., Glauser, D. L., Colaco, S., May, J. S. & Stevenson, P. G. (2009b). Glycoprotein L sets the neutralization profile of murid herpesvirus-4. J Gen Virol 90, 1202-1214.
51. Gottschalk, S., Rooney, C. M. & Heslop, H. E. (2005). Post-transplant lymphoproliferative disorders. Annu Rev Med 56, 29-44.
52. Hadinoto, V., Shapiro, M., Greenough, T. C., Sullivan, J. L., Luzuriaga, K. & Thorley-Lawson, D. A. (2008). On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 111, 1420-1427.
53. Haque, T., Wilkie, G. M., Jones, M. M., Higgins, C. D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M. & other authors (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive post-transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110, 1123-1131.
54. Hayashida, I., Nagafuchi, S., Hayashi, Y., Kino, Y., Mori, R., Oda, H., Ohtomo, N. & Tashiro, A. (1982). Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: requirement of Fc portion of antibody. Microbiol Immunol 26, 497-509.
55. Hengel, H., Brune, W. & Koszinowski, U. H. (1998). Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol 6, 190-197.
56. Hengel, H., Reusch, U., Geginat, G., Holtappels, R., Ruppert, T., Hellebrand, E. & Koszinowski, U. H. (2000). Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J Virol 74, 7861-7868.
57. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204, 1863-1873.
58. Hoagland, R. J. (1964). The incubation period of infectious mononucleosis. Am J Public Health Nations Health 54, 1699-1705.
59. + T lymphocytes. Proc Natl Acad Sci U S A 96, 7508-7513.
60. Janz, A., Oezel, M., Kurzeder, C., Mautner, J., Pich, D., Kost, M., Hammerschmidt, W. & Delecluse, H. J. (2000). Infectious Epstein- Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 74, 10142-10152.
61. + T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J Virol 82, 9678-9688.
62. + T cells over time. J Immunol 170, 2022-2029.
63. Kayhan, B., Yager, E. J., Lanzer, K., Cookenham, T., Jia, Q., Wu, T. T., Woodland, D. L., Sun, R. & Blackman, M. A. (2007). A replication-deficient murine gamma-herpesvirus blocked in late viral gene expression can establish latency and elicit protective cellular immunity. J Immunol 179, 8392-8402.
64. Khan, N., Shariff, N., Cobbold, M., Bruton, R., Ainsworth, J. A., Sinclair, A. J., Nayak, L. & Moss, P. A. (2002). Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169, 1984-1992.
65. Kim, I. J., Flaño, E., Woodland, D. L. & Blackman, M. A. (2002). Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol 168, 3958-3964.
66. Klein, R. J. (1982). Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. Am J Med 73, 138-142.
67. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322, 268-271.
68. Kozuch, O., Reichel, M., Lesso, J., Remenova, A., Labuda, M., Lysy, J. & Mistrikova, J. (1993). Further isolation of murine herpesviruses from small mammals in southwestern Slovakia. Acta Virol 37, 101-105.
69. Lee, H., Guo, J., Li, M., Choi, J. K., DeMaria, M., Rosenzweig, M. & Jung, J. U. (1998). Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol 18, 5219-5228.
70. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald- Mullen, P. M., Klein, G., Kurilla, M. G. & Masucci, M. G. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688.
71. Liu, L., Usherwood, E. J., Blackman, M. A. & Woodland, D. L. (1999). T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. J Virol 73, 9849-9857.
72. Lybarger, L., Wang, X., Harris, M. R., Virgin, H. W. & Hansen, T. H. (2003). Virus subversion of the MHC class I peptide-loading complex. Immunity 18, 121-130.
73. Marques, S., Efstathiou, S., Smith, K. G., Haury, M. & Simas, J. P. (2003). Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes. J Virol 77, 7308-7318.
74. + T cell epitope sets the long-term latent load of a murid herpesvirus. PLoS Pathog 4, e1000177.
75. + T helper cells. Eur J Immunol 34, 2500-2509.
76. McClellan, J. S., Tibbetts, S. A., Gangappa, S., Brett, K. A. & Virgin, H. W. (2004). Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency. J Virol 78, 6836-6845.
77. Medawar, P. B. (1948). Immunity to homologous grafted skin: the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29, 58-69.
78. Milho, R., Smith, C. M., Marques, S., Alenquer, M., May, J. S., Gillet, L., Gaspar, M., Efstathiou, S., Simas, J. P. & Stevenson, P. G. (2009). In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 90, 21-32.
79. Moorman, N. J., Willer, D. O. & Speck, S. H. (2003). The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol 77, 10295-10303.
80. Moser, J. M., Farrell, M. L., Krug, L. T., Upton, J. W. & Speck, S. H. (2006). A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge. J Virol 80, 1592-1598.
81. Nash, A. A., Dutia, B. M., Stewart, J. P. & Davison, A. J. (2001). Natural history of murine gamma-herpesvirus infection. Philos Trans R Soc Lond B Biol Sci 356, 569-579.
82. Nicholas, J. (2005). Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res 25, 373-383.
83. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 77, 12088-12104.
84. Orr, M. T., Mathis, M. A., Lagunoff, M., Sacks, J. A. & Wilson, C. B. (2007). CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I. Cell Host Microbe 2, 172-180.
85. Parry, C. M., Simas, J. P., Smith, V. P., Stewart, C. A., Minson, A. C., Efstathiou, S. & Alcami, A. (2000). A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 191, 573-578.
86. Polić, B., Jonjić, S., Pavić, I., Crnković, I., Zorica, I., Hengel, H., Lucin, P. & Koszinowski, U. H. (1996). Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol 77, 217-225.
87. Polić, B., Hengel, H., Krmpotić, A., Trgovcich, J., Pavić, I., Luccaronin, P., Jonjić, S. & Koszinowski, U. H. (1998). Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188, 1047-1054.
88. Proença, J. T., Coleman, H. M., Connor, V., Winton, D. J. & Efstathiou, S. (2008). A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurones. J Gen Virol 89, 2965-2974.
89. Reddehase, M. J., Simon, C. O., Seckert, C. K., Lemmermann, N. & Grzimek, N. K. (2008). Murine model of cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 325, 315-331.
90. Redwine, J. M., Buchmeier, M. J. & Evans, C. F. (2001). In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol 159, 1219-1224.
91. Rice, J., de Lima, B., Stevenson, F. K. & Stevenson, P. G. (2002). A gamma-herpesvirus immune evasion gene allows tumor cells in vivo to escape attack by cytotoxic T cells specific for a tumor epitope. Eur J Immunol 32, 3481-3487.
92. Rickinson, A. B. & Moss, D. J. (1997). Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15, 405-431.
93. Rodrigues, L., Pires de Miranda, M., Caloca, M. J., Bustelo, X. R. & Simas, J. P. (2006). Activation of Vav by the gammaherpesvirus M2 protein contributes to the establishment of viral latency in B lymphocytes. J Virol 80, 6123-6135.
94. Rosa, G. T., Gillet, L., Smith, C. M., de Lima, B. D. & Stevenson, P. G. (2007). IgG Fc receptors provide an alternative infection route for murine gamma-herpesvirus-68. PLoS One 2, e560.
95. Roughan, J. E. & Thorley-Lawson, D. A. (2009). The intersection of Epstein-Barr virus with the germinal center. J Virol 83, 3968-3976.
96. Sample, J., Henson, E. B. & Sample, C. (1992). The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J Virol 66, 4654-4661.
97. Sarawar, S. R., Cardin, R. D., Brooks, J. W., Mehrpooya, M., Hamilton-Easton, A. M., Mo, X. Y. & Doherty, P. C. (1997). Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. J Virol 71, 3916-3921.
98. Shannon-Lowe, C. D., Neuhierl, B., Baldwin, G., Rickinson, A. B. & Delecluse, H. J. (2006). Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci U S A 103, 7065-7070.
99. Simmons, A. & Tscharke, D. C. (1992). Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 175, 1337-1344.
100. Skehel, J. J. & Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531-569.
101. + T cells specific for a model latency-associated antigen fail to control a gammaherpesvirus in vivo. Eur J Immunol 36, 3186-3197.
102. Smith, C. M., Gill, M. B., May, J. S. & Stevenson, P. G. (2007). Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells. PLoS One 2, e1048.
103. Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Le'onard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F. & Denis, M. (2007). Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196, 1749-1753.
104. Sparks-Thissen, R. L., Braaten, D. C., Kreher, S., Speck, S. H. & Virgin, H. W. (2004). An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection. J Virol 78, 6827-6835.
105. Sparks-Thissen, R. L., Braaten, D. C., Hildner, K., Murphy, T. L., Murphy, K. M. & Virgin, H. W. (2005). CD4 T cell control of acute and latent murine gammaherpesvirus infection requires IFN gamma. Virology 338, 201-208.
106. Stebbing, J., Bourboulia, D., Johnson, M., Henderson, S., Williams, I., Wilder, N., Tyrer, M., Youle, M., Imami, N. & other authors (2003). Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 77, 4306-4314.
107. Steed, A., Buch, T., Waisman, A. & Virgin, H. W. (2007). Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol 81, 6134-6140.
108. Stevenson, P. G. (2004). Immune evasion by gamma-herpesviruses. Curr Opin Immunol 16, 456-462.
109. Stevenson, P. G. & Efstathiou, S. (2005). Immune mechanisms in murine gammaherpesvirus-68 infection. Viral Immunol 18, 445-456.
110. Stevenson, P. G., Hawke, S., Sloan, D. J. & Bangham, C. R. (1997a). The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 71, 145-151.
111. + memory T cells in an immunoprivileged site. Eur J Immunol 27, 3259-3268.
112. + T cell numbers are maintained during gamma-herpesvirus reactivation in CD4-deficient mice. Proc Natl Acad Sci U S A 95, 15565-15570.
113. + T cells. J Gen Virol 80, 477-483.
114. + T cell response during acute and persistent murine gamma-herpesvirus infection. Eur J Immunol 29, 1059-1067.
115. + T cell response primed to a lytic-phase epitope. Proc Natl Acad Sci U S A 96, 9281-9286.
116. + T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol 3, 733-740.
117. Stewart, J. P., Micali, N., Usherwood, E. J., Bonina, L. & Nash, A. A. (1999). Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Vaccine 17, 152-157.
118. Sun, C. C. & Thorley-Lawson, D. A. (2007). Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 81, 13566-13577.
119. Takahashi, M. (2001). 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr Drugs 3, 285-292.
120. Tarakanova, V. L., Suarez, F., Tibbetts, S. A., Jacoby, M. A., Weck, K. E., Hess, J. L., Speck, S. H. & Virgin, H. W. (2005). Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB β2 microglobulin-deficient mice. J Virol 79, 14668-14679.
121. Thompson, R. L., Preston, C. M. & Sawtell, N. M. (2009). De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog 5, e1000352.
122. Thomsen, A. R., Johansen, J., Marker, O. & Christensen, J. P. (1996). Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J Immunol 157, 3074-3080.
123. Thorley-Lawson, D. A. (2001). Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1, 75-82.
124. Thorley-Lawson, D. A. & Geilinger, K. (1980). Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A 77, 5307-5311.
125. Tibbetts, S. A., van Dyk, L. F., Speck, S. H. & Virgin, H. W. (2002). Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J Virol 76, 7125-7132.
126. Tibbetts, S. A., McClellan, J. S., Gangappa, S., Speck, S. H. & Virgin, H. W. (2003). Effective vaccination against long-term gammaherpesvirus latency. J Virol 77, 2522-2529.
127. Tibbetts, S. A., Suarez, F., Steed, A. L., Simmons, J. A. & Virgin, H. W. (2006). A gamma-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells. Virology 353, 210-219.
128. Tomazin, R., van Schoot, N. E., Goldsmith, K., Jugovic, P., Sempé, P., Früh, K. & Johnson, D. C. (1998). Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 72, 2560-2563.
129. + T cells is inefficient in the absence of B cells. J Virol 72, 882-885.
130. Turner, A., Bruun, B., Minson, T. & Browne, H. (1998). Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J Virol 72, 873-875.
131. Usherwood, E. J., Ross, A. J., Allen, D. J. & Nash, A. A. (1996). Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J Gen Virol 77, 627-630.
132. Usherwood, E. J., Ward, K. A., Blackman, M. A., Stewart, J. P. & Woodland, D. L. (2001). Latent antigen vaccination in a model gammaherpesvirus infection. J Virol 75, 8283-8288.
133. Usherwood, E. J., Meadows, S. K., Crist, S. G., Bellfy, S. C. & Sentman, C. L. (2005). Control of murine gammaherpesvirus infection is independent of NK cells. Eur J Immunol 35, 2956-2961.
134. van Berkel, V., Barrett, J., Tiffany, H. L., Fremont, D. H., Murphy, P. M., McFadden, G., Speck, S. H. & Virgin, H. W. (2000). Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 74, 6741-6747.
135. Verjans, G. M., Hintzen, R. Q., van Dun, J. M., Poot, A., Milikan, J. C., Laman, J. D., Langerak, A. W., Kinchington, P. R. & Osterhaus, A. D. (2007). Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 104, 3496-3501.
136. Virgin, H. W. & Speck, S. H. (1999). Unravelling immunity to gammaherpesviruses: a new model for understanding the role of immunity in chronic virus infection. Curr Opin Immunol 11, 371-379.
137. Virgin, H. W., Latreille, P., Wamsley, P., Hallsworth, K., Weck, K. E., Dal Canto, A. J. & Speck, S. H. (1997). Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 71, 5894-5904.
138. + T lymphocytes. J Exp Med 199, 459-470.
139. Wallace, M. E., Keating, R., Heath, W. R. & Carbone, F. R. (1999). The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 73, 7619-7626.
140. Weck, K. E., Dal Canto, A. J., Gould, J. D., O'Guin, A. K., Roth, K. A., Saffitz, J. E., Speck, S. H. & Virgin, H. W. (1997). Murine gammaherpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 3, 1346-1353.
141. Wilson, S. J., Tsao, E. H., Webb, B. L., Ye, H., Dalton-Griffin, L., Tsantoulas, C., Gale, C. V., Du, M. Q., Whitehouse, A. & Kellam, P. (2007). X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J Virol 81, 13578-13586.
142. Yao, Q. Y., Ogan, P., Rowe, M., Wood, M. & Rickinson, A. B. (1989a). The Epstein-Barr virus: host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. Int J Cancer 43, 61-66.
143. Yao, Q. Y., Ogan, P., Rowe, M., Wood, M. & Rickinson, A. B. (1989b). Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 43, 67-71.
144. Yewdell, J. W. & Hill, A. B. (2002). Viral interference with antigen presentation. Nat Immunol 3, 1019-1025.
145. Yin, Y., Manoury, B. & Fahraeus, R. (2003). Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301, 1371-1374.
146. + T lymphocytes. Cell 77, 525-535.
147. Zinkernagel, R. M. & Hengartner, H. (2006). Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev 211, 310-319.